John Domack News Today

Talk to their doctors. >> all right. dr. john, thanks very much. when we return, metas new app threads draws millions, but will it landmark draws millions, but will it landmark zuckerberg in court? ♪ i have type 2 diabetes, ♪ ♪ but i manage it well. ♪ ♪ its a a little pilill with a big storory to tell.l. ♪ ♪ i take e once-dailyly jardiaiance, ♪ ♪ at each d days staaaaart.♪ ♪ a as time wenent on itit was easy y to seee ♪ ♪ imm lowering g my a1c. ♪

I think its helped me. >> reporter: his cognitive function has declined slightly, they say, but not by much. >> we get that its not a cure. but there was nothing when we got our diagnosis, nothing. now there is something that we can do. >> reporter: it gives you hope? >> uh-huh, sure. >> yeah, unbelievably. i mean, we had none. >> reporter: since john is still in a trial, theyre not paying for leqembi, but the list price is 26,500 a year. medicare plans to provide coverage as long as a doctor ag...

>> reporter: theyre traveling to london in august. >> alzheimers threw us for a loop. this drug has thrown us a lifeline. >> reporter: kate snow, nbc news, new york. in the wake of last years tripledemic, health officials are trying to prevent a repeat this fall. chief medical correspondent dr. john torres is here. john, last year we saw flu, rsv and covid all at the same time. >> lester, last winter we had the three virus, influenza, covid, rsv. they all ended up peaking at the same time. alt...

First-of-its-kind drug. it offers real hope for slowing progression of the disease. here is kate snow. >> reporter: its the first time a drug meant to slow the progression of alzheimers disease has ever been granted full regulatory approval. in a clinical trial involving about 1800 patients in the early stages of alzheimers, the drug leqembi slowed cognitive decline by 27% over an 18-month period, compared to people who took a placebo. >> i really cannot overstate how important today is. this is...